By Keith L. Carson
Volume 13, Issue 3 (Fall 2014)
While I could be deluding myself with wishful thinking, I may be seeing the “new normal” evolving for the biotech industry. The “new normal” may very well be that the mass closing of R&D facilities and the cancellation of major programs is freeing up the CSOs and other entrepreneurs who will start their own companies…
Citation: Carson KL. From the Editor-in-Chief: Building Businesses and Developing Strategic Partnerships. BioProcess J, 2014; 13(3): 5. https://doi.org/10.12665/J133.Carson
Posted online July 27, 2026